JP2018508592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508592A5 JP2018508592A5 JP2018500276A JP2018500276A JP2018508592A5 JP 2018508592 A5 JP2018508592 A5 JP 2018508592A5 JP 2018500276 A JP2018500276 A JP 2018500276A JP 2018500276 A JP2018500276 A JP 2018500276A JP 2018508592 A5 JP2018508592 A5 JP 2018508592A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- nervous system
- disease
- central nervous
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 12
- 208000015114 central nervous system disease Diseases 0.000 claims 10
- 229940002612 prodrug Drugs 0.000 claims 7
- 239000000651 prodrug Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 208000019901 Anxiety disease Diseases 0.000 claims 6
- 206010012289 Dementia Diseases 0.000 claims 6
- 208000012902 Nervous system disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 3
- 229910052805 deuterium Inorganic materials 0.000 claims 3
- 230000004968 inflammatory condition Effects 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 206010000605 Acrophobia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000031091 Amnestic disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 206010012218 Delirium Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 201000007737 Retinal degeneration Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 230000008832 photodamage Effects 0.000 claims 2
- 210000001525 retina Anatomy 0.000 claims 2
- 230000004258 retinal degeneration Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- IBYCYJFUEJQSMK-CVMQCHJJSA-N 6-chloro-4-methyl-N-(1,1,2,2,2-pentadeuterioethyl)-4-(2,3,4,5,6-pentadeuteriophenyl)-1H-3,1-benzoxazin-2-imine Chemical compound ClC=1C=CC2=C(C(OC(=N2)NC(C([2H])([2H])[2H])([2H])[2H])(C2=C(C(=C(C(=C2[2H])[2H])[2H])[2H])[2H])C)C=1 IBYCYJFUEJQSMK-CVMQCHJJSA-N 0.000 claims 1
- IBYCYJFUEJQSMK-WNWXXORZSA-N 6-chloro-4-methyl-N-(1,1,2,2,2-pentadeuterioethyl)-4-phenyl-1H-3,1-benzoxazin-2-imine Chemical compound ClC=1C=CC2=C(C(OC(=N2)NC(C([2H])([2H])[2H])([2H])[2H])(C2=CC=CC=C2)C)C=1 IBYCYJFUEJQSMK-WNWXXORZSA-N 0.000 claims 1
- IBYCYJFUEJQSMK-XKFZCJJYSA-N 6-chloro-N-(1,1,2,2,2-pentadeuterioethyl)-4-(2,3,4,5,6-pentadeuteriophenyl)-4-(trideuteriomethyl)-1H-3,1-benzoxazin-2-imine Chemical compound ClC=1C=CC2=C(C(OC(=N2)NC(C([2H])([2H])[2H])([2H])[2H])(C2=C(C(=C(C(=C2[2H])[2H])[2H])[2H])[2H])C([2H])([2H])[2H])C=1 IBYCYJFUEJQSMK-XKFZCJJYSA-N 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- SEACZJILJZXHEV-UHFFFAOYSA-N CC1(OC(N)=NC2=C1C=CC=C2)C1=CC=CC=C1 Chemical compound CC1(OC(N)=NC2=C1C=CC=C2)C1=CC=CC=C1 SEACZJILJZXHEV-UHFFFAOYSA-N 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021118 Hypotonia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010027944 Mood disorder due to a general medical condition Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000003028 Stuttering Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000022257 bipolar II disease Diseases 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 230000007213 cerebrovascular event Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- -1 ethyl -1,1-d 2 Chemical class 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000008991 intestinal motility Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000000155 isotopic effect Effects 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 230000036640 muscle relaxation Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 206010039722 scoliosis Diseases 0.000 claims 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000001148 spastic effect Effects 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical class C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 208000018726 traumatic encephalopathy Diseases 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562135979P | 2015-03-20 | 2015-03-20 | |
| US62/135,979 | 2015-03-20 | ||
| PCT/US2016/023231 WO2016154039A1 (en) | 2015-03-20 | 2016-03-18 | Deuterated analogs of etifoxine, their derivatives and uses therof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020139537A Division JP2021001174A (ja) | 2015-03-20 | 2020-08-20 | エチホキシンの重水素化類似体、それらの誘導体、およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508592A JP2018508592A (ja) | 2018-03-29 |
| JP2018508592A5 true JP2018508592A5 (enExample) | 2019-04-25 |
| JP6762507B2 JP6762507B2 (ja) | 2020-09-30 |
Family
ID=56977741
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018500276A Active JP6762507B2 (ja) | 2015-03-20 | 2016-03-18 | エチホキシンの重水素化類似体、それらの誘導体、およびそれらの使用 |
| JP2020139537A Pending JP2021001174A (ja) | 2015-03-20 | 2020-08-20 | エチホキシンの重水素化類似体、それらの誘導体、およびそれらの使用 |
| JP2022176234A Active JP7376668B2 (ja) | 2015-03-20 | 2022-11-02 | エチホキシンの重水素化類似体、それらの誘導体、およびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020139537A Pending JP2021001174A (ja) | 2015-03-20 | 2020-08-20 | エチホキシンの重水素化類似体、それらの誘導体、およびそれらの使用 |
| JP2022176234A Active JP7376668B2 (ja) | 2015-03-20 | 2022-11-02 | エチホキシンの重水素化類似体、それらの誘導体、およびそれらの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10080755B2 (enExample) |
| EP (1) | EP3347006B1 (enExample) |
| JP (3) | JP6762507B2 (enExample) |
| KR (1) | KR102290766B1 (enExample) |
| CN (1) | CN107530323B (enExample) |
| AU (2) | AU2016235495B2 (enExample) |
| BR (1) | BR112017020081B1 (enExample) |
| CA (1) | CA2979853C (enExample) |
| DK (1) | DK3347006T3 (enExample) |
| ES (1) | ES2928396T3 (enExample) |
| HR (1) | HRP20221240T1 (enExample) |
| HU (1) | HUE060240T2 (enExample) |
| IL (2) | IL270627B2 (enExample) |
| LT (1) | LT3347006T (enExample) |
| MX (1) | MX383647B (enExample) |
| PL (1) | PL3347006T3 (enExample) |
| PT (1) | PT3347006T (enExample) |
| RS (1) | RS63654B1 (enExample) |
| SI (1) | SI3347006T1 (enExample) |
| SM (1) | SMT202200407T1 (enExample) |
| WO (1) | WO2016154039A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3347006T (pt) * | 2015-03-20 | 2022-10-17 | Gaba Therapeutics Inc | Análogos deuterados de etifoxina, os seus derivados e suas utilizações |
| US10420773B2 (en) | 2017-09-26 | 2019-09-24 | Ovid Therapeutics Inc. | Methods of treating developmental disorders and/or seizure disorders with etifoxine |
| WO2019183564A1 (en) * | 2018-03-23 | 2019-09-26 | Concert Pharmaceuticals, Inc. | DEUTERATED ANALOGS OF D-β-HYDROXYBUTYRIC ACID AND USES THEREOF |
| US20190350882A1 (en) * | 2018-05-18 | 2019-11-21 | Ovid Therapeutics, Inc. | Methods of treating attention deficit hyperactivity disorder |
| CN112125862A (zh) * | 2019-06-25 | 2020-12-25 | 上海安谱实验科技股份有限公司 | 一种稳定同位素标记的阿特拉津-d5及其合成方法 |
| US11534434B2 (en) | 2019-11-15 | 2022-12-27 | Karuna Therapeutics, Inc. | Xanomeline derivatives and methods for treating neurological disorders |
| CN115806579B (zh) * | 2021-09-14 | 2025-10-24 | 南京迈诺威医药科技有限公司 | 一种水溶性别孕烷醇酮衍生物及其制备方法和用途 |
| WO2023218251A1 (en) * | 2022-05-10 | 2023-11-16 | Clearsynth Labs Limied | Novel deuterium-enriched nefazodone analogues and method for preparing thereof |
| KR20250111122A (ko) * | 2022-10-24 | 2025-07-22 | 가바 테라퓨틱스, 아이엔씨. | 에티폭신의 중수소화 유사체 및 대사의 자가유도 없이 투여하는 방법 |
| WO2025085958A1 (en) * | 2023-10-23 | 2025-05-01 | Glomesh Intl Pty Ltd | A module for mounting items |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1670772C3 (de) | 1966-11-24 | 1978-04-20 | Hoechst Ag, 6000 Frankfurt | 4H-3,1-Benzoxazin-Derivate, deren Salze und pharmazeutische Präparate |
| FR2888748B1 (fr) * | 2005-07-19 | 2007-10-12 | Biocodex | Composes neuroprotecteurs et compositions pharmaceutiques les comprenant |
| WO2007109289A1 (en) * | 2006-03-20 | 2007-09-27 | Xytis Inc. | Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use |
| WO2007109288A2 (en) * | 2006-03-20 | 2007-09-27 | Xytis Inc. | Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use |
| JP2011001308A (ja) * | 2009-06-19 | 2011-01-06 | Research Foundation Itsuu Laboratory | 重水素化カルボスチリル化合物 |
| CN104610144A (zh) * | 2010-07-09 | 2015-05-13 | 泰华制药工业有限公司 | 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途 |
| US20140121407A1 (en) | 2011-07-05 | 2014-05-01 | Research Foundation Itsuu Laboratory | Deuterated phenylpropionic acid derivative |
| FR3016881B1 (fr) | 2014-01-29 | 2016-03-04 | Biocodex | Traitement des degenerescences et des lesions photo-induites de la retine |
| PT3347006T (pt) * | 2015-03-20 | 2022-10-17 | Gaba Therapeutics Inc | Análogos deuterados de etifoxina, os seus derivados e suas utilizações |
-
2016
- 2016-03-18 PT PT167694371T patent/PT3347006T/pt unknown
- 2016-03-18 SI SI201631611T patent/SI3347006T1/sl unknown
- 2016-03-18 KR KR1020177028263A patent/KR102290766B1/ko active Active
- 2016-03-18 RS RS20220948A patent/RS63654B1/sr unknown
- 2016-03-18 HU HUE16769437A patent/HUE060240T2/hu unknown
- 2016-03-18 LT LTEPPCT/US2016/023231T patent/LT3347006T/lt unknown
- 2016-03-18 IL IL270627A patent/IL270627B2/en unknown
- 2016-03-18 PL PL16769437.1T patent/PL3347006T3/pl unknown
- 2016-03-18 ES ES16769437T patent/ES2928396T3/es active Active
- 2016-03-18 WO PCT/US2016/023231 patent/WO2016154039A1/en not_active Ceased
- 2016-03-18 EP EP16769437.1A patent/EP3347006B1/en active Active
- 2016-03-18 JP JP2018500276A patent/JP6762507B2/ja active Active
- 2016-03-18 AU AU2016235495A patent/AU2016235495B2/en active Active
- 2016-03-18 DK DK16769437.1T patent/DK3347006T3/da active
- 2016-03-18 SM SM20220407T patent/SMT202200407T1/it unknown
- 2016-03-18 MX MX2017011978A patent/MX383647B/es unknown
- 2016-03-18 CN CN201680028306.5A patent/CN107530323B/zh active Active
- 2016-03-18 BR BR112017020081-3A patent/BR112017020081B1/pt active IP Right Grant
- 2016-03-18 HR HRP20221240TT patent/HRP20221240T1/hr unknown
- 2016-03-18 US US15/557,748 patent/US10080755B2/en active Active
- 2016-03-18 CA CA2979853A patent/CA2979853C/en active Active
-
2017
- 2017-09-18 IL IL254567A patent/IL254567B/en active IP Right Grant
-
2018
- 2018-09-21 US US16/138,509 patent/US10736901B2/en active Active
-
2020
- 2020-03-09 AU AU2020201728A patent/AU2020201728B2/en active Active
- 2020-08-07 US US16/988,586 patent/US11672805B2/en active Active
- 2020-08-20 JP JP2020139537A patent/JP2021001174A/ja active Pending
-
2022
- 2022-11-02 JP JP2022176234A patent/JP7376668B2/ja active Active
-
2023
- 2023-05-01 US US18/141,999 patent/US12433896B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221240T1 (hr) | Deuterirani analozi etifoksina, njihovi derivati i njihove uporabe | |
| JP2014526469A5 (enExample) | ||
| JP6321825B2 (ja) | 神経形成を刺激することができるｎ−フェニル−ラクタム誘導体及び神経障害の処置におけるそれらの使用 | |
| JP6434425B2 (ja) | Ｓ１ｐ調節剤 | |
| JP5377285B2 (ja) | キラルアミドおよびキラルアミンの調製 | |
| JP2017531020A5 (enExample) | ||
| JP2021519267A5 (enExample) | ||
| EA201692558A1 (ru) | Производные индолин-2-она или пирролопиридин-2-она | |
| JP2010529081A5 (enExample) | ||
| JP2023539125A5 (enExample) | ||
| JP2014518552A5 (enExample) | ||
| RU2013124827A (ru) | Производные индола и способ их получения | |
| JP2022524111A5 (enExample) | ||
| RU2013147917A (ru) | Новые модуляторы кортикальной дофаминергической и опосредованной nmda-рецептором глутаматергической нейротрансмиссии | |
| JP2022512373A5 (enExample) | ||
| RU2011107443A (ru) | Индаценовые соединения, фармацевтическая композиция и лекарственное средство на их основе, способ их получения и способ лечения или профилактики состояний, связанных с нарушением функционирования систем, регулируемых мелатонином, с их помощью | |
| JP2019535715A5 (enExample) | ||
| PH12016500605A1 (en) | Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders | |
| JP2020520936A5 (enExample) | ||
| JP2008519056A5 (enExample) | ||
| JP2012509860A5 (enExample) | ||
| RU2010120847A (ru) | Соединения индолина, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний | |
| JPWO2016027757A1 (ja) | 新規２−アミノベンゾイル誘導体 | |
| UA99500C2 (en) | 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine | |
| JP2023533932A5 (enExample) |